KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to -$7.1 million.

  • Adaptive Biotechnologies' Cash from Operations rose 7366.71% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.5 million, marking a year-over-year increase of 4479.68%. This contributed to the annual value of -$95.2 million for FY2024, which is 3909.32% up from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Cash from Operations is -$7.1 million, which was up 7366.71% from -$12.4 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Cash from Operations high stood at -$7.1 million for Q3 2025, and its period low was -$64.5 million during Q1 2022.
  • Its 5-year average for Cash from Operations is -$35.6 million, with a median of -$37.2 million in 2021.
  • Per our database at Business Quant, Adaptive Biotechnologies' Cash from Operations tumbled by 8428.46% in 2021 and then soared by 7366.71% in 2025.
  • Adaptive Biotechnologies' Cash from Operations (Quarter) stood at -$53.8 million in 2021, then soared by 44.23% to -$30.0 million in 2022, then increased by 10.28% to -$26.9 million in 2023, then soared by 53.62% to -$12.5 million in 2024, then surged by 42.94% to -$7.1 million in 2025.
  • Its Cash from Operations stands at -$7.1 million for Q3 2025, versus -$12.4 million for Q2 2025 and -$28.5 million for Q1 2025.